Related Experiment Videos
Potent and selective inhibition of gene expression by an antisense heptanucleotide
R W Wagner1, M D Matteucci, D Grant
1Gilead Sciences, Foster City, CA 94404, USA.
Abstract:
Factors that govern the specificity of an antisense oligonucleotide (ON) for its target RNA include accessibility of the targeted RNA to ON binding, stability of ON/RNA complexes in cells, and susceptibility of the ON/RNA complex to RNase H cleavage. ON specificity is generally proposed to be dependent on its length. To date, virtually all previous antisense experiments have used 12-25 nt-long ONs. We explored the antisense activity and specificity of short (7 and 8 nt) ONs modified with C-5 propyne pyrimidines and phosphorothioate internucleotide linkages. Gene-selective, mismatch sensitive, and RNase H-dependent inhibition was observed for a heptanucleotide ON. We demonstrated that the flanking sequences of the target RNA are a major determinant of specificity. The use of shorter ONs as antisense agents has the distinct advantage of simplified synthesis. These results may lead to a general, cost-effective solution to the development of antisense ONs as therapeutic agents.
Insights
Shorter antisense oligonucleotides (ONs), modified with C-5 propyne pyrimidines, demonstrate gene-selective inhibition. Target RNA flanking sequences are key to specificity, offering a cost-effective therapeutic development approach.
Area of Science:
- Molecular Biology
- Oligonucleotide Therapeutics
- RNA Biology
Background:
- Antisense oligonucleotide (ON) specificity is crucial for therapeutic applications.
- ON specificity is influenced by target RNA accessibility, complex stability, and RNase H cleavage.
- Traditional antisense ONs range from 12 to 25 nucleotides (nt) in length.
Purpose of the Study:
- To investigate the antisense activity and specificity of short (7 and 8 nt) ONs.
- To evaluate the impact of C-5 propyne pyrimidines and phosphorothioate linkages on ON performance.
- To identify key determinants of specificity for short antisense ONs.
Main Methods:
- Synthesis of modified short antisense oligonucleotides (7 and 8 nt).
- Testing antisense activity and specificity in cellular models.
- Analysis of RNase H-dependent cleavage and mismatch sensitivity.
Main Results:
- A heptanucleotide ON exhibited gene-selective, mismatch-sensitive, and RNase H-dependent inhibition.
- Flanking sequences of the target RNA were identified as a major determinant of ON specificity.
- Shortened ONs offer advantages in synthesis simplification.
Conclusions:
- Shortened antisense oligonucleotides can be effective and specific therapeutic agents.
- Target RNA flanking sequences play a critical role in dictating ON specificity.
- This approach presents a potentially cost-effective strategy for developing antisense ON therapies.